Literature DB >> 12668360

Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia.

Joseph H Callicott1, Michael F Egan, Venkata S Mattay, Alessandro Bertolino, Ashley D Bone, Beth Verchinksi, Daniel R Weinberger.   

Abstract

OBJECTIVE: The identification of neurobiological intermediate phenotypes may hasten the search for susceptibility genes in complex psychiatric disorders such as schizophrenia. Earlier family studies have suggested that deficits in executive cognition and working memory may be related to genetic susceptibility for schizophrenia, but the biological basis for this behavioral phenotype has not been identified.
METHOD: The authors used functional magnetic resonance imaging (fMRI) during performance of the N-back working memory task to assess working memory-related cortical physiology in nonschizophrenic, cognitively intact siblings of patients with schizophrenia. They compared 23 unaffected siblings of schizophrenic patients to 18 matched comparison subjects. As a planned replication, they studied another 25 unaffected siblings and 15 comparison subjects.
RESULTS: In both cohorts, there were no group differences in working memory performance. Nevertheless, both groups of siblings showed an exaggerated physiological response in the right dorsolateral prefrontal cortex that was qualitatively similar to results of earlier fMRI studies of patients with schizophrenia.
CONCLUSIONS: These fMRI data provide direct evidence of a primary physiological abnormality in dorsolateral prefrontal cortex function in individuals at greater genetic risk for schizophrenia, even in the absence of a manifest cognitive abnormality. This exaggerated fMRI response implicates inefficient processing of memory information at the level of intrinsic prefrontal circuitry, similar to earlier findings in patients with schizophrenia. These data predict that inheritance of alleles that contribute to inefficient prefrontal information processing will increase risk for schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668360     DOI: 10.1176/appi.ajp.160.4.709

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  142 in total

Review 1.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

Review 2.  Voxel-wise meta-analysis of fMRI studies in patients at clinical high risk for psychosis.

Authors:  Paolo Fusar-Poli
Journal:  J Psychiatry Neurosci       Date:  2012-02       Impact factor: 6.186

3.  Dissociable and common deficits in inhibitory control in schizophrenia and bipolar disorder.

Authors:  Tessa Christodoulou; Lambros Messinis; Panagiotis Papathanasopoulos; Sophia Frangou
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-04-22       Impact factor: 5.270

4.  Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin.

Authors:  Andrew J Greenshaw
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

Review 5.  Approaches for adolescents with an affected family member with schizophrenia.

Authors:  Vaibhav A Diwadkar; Konasale M Prasad; Matcheri S Keshavan
Journal:  Curr Psychiatry Rep       Date:  2004-08       Impact factor: 5.285

6.  Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.

Authors:  Michael F Egan; Richard E Straub; Terry E Goldberg; Imtiaz Yakub; Joseph H Callicott; Ahmad R Hariri; Venkata S Mattay; Alessandro Bertolino; Thomas M Hyde; Cynthia Shannon-Weickert; Mayada Akil; Jeremy Crook; Radha Krishna Vakkalanka; Rishi Balkissoon; Richard A Gibbs; Joel E Kleinman; Daniel R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

Review 7.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  Evidence that altered amygdala activity in schizophrenia is related to clinical state and not genetic risk.

Authors:  Roberta Rasetti; Venkata S Mattay; Lisa M Wiedholz; Bhaskar S Kolachana; Ahmad R Hariri; Joseph H Callicott; Andreas Meyer-Lindenberg; Daniel R Weinberger
Journal:  Am J Psychiatry       Date:  2008-12-15       Impact factor: 18.112

9.  Impact of interacting functional variants in COMT on regional gray matter volume in human brain.

Authors:  Robyn Honea; Beth A Verchinski; Lukas Pezawas; Bhaskar S Kolachana; Joseph H Callicott; Venkata S Mattay; Daniel R Weinberger; Andreas Meyer-Lindenberg
Journal:  Neuroimage       Date:  2008-11-21       Impact factor: 6.556

10.  Effects of neuregulin 3 genotype on human prefrontal cortex physiology.

Authors:  Heike Tost; Joseph H Callicott; Roberta Rasetti; Radhakrishna Vakkalanka; Venkata S Mattay; Daniel R Weinberger; Amanda J Law
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.